Patent: 9,950,042
✉ Email this page to a colleague
Summary for Patent: 9,950,042
| Title: | Extended length botulinum toxin formulation for human or mammalian use |
| Abstract: | An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule is disclosed. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed. |
| Inventor(s): | Borodic; Gary E. (Quincy, MA) |
| Assignee: | REVANCE THERAPEUTICS, INC. (Newark, CA) |
| Application Number: | 14/754,268 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,950,042
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Omrix Biopharmaceuticals Ltd | EVITHROM | thrombin, topical (human) | Solution | 125247 | 08/27/2007 | ⤷ Try a Trial | 2028-12-04 |
| Omrix Biopharmaceuticals Ltd | EVITHROM | thrombin, topical (human) | For Injection | 125247 | 09/17/2009 | ⤷ Try a Trial | 2028-12-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
